Efficacy of BNT162b2 vaccine against Omicron in children aged 5 to 11 years

  • 1. Kozlov m. Does Omicron hit kids more? Scientists are trying to find out. temper nature 2022 February 4 (Electronic publishing before printing).

  • 2. something dAnd the Whitaker mAnd the Marks KG, and others. Hospitalization of Children 5-11 Years Old with Laboratory-Confirmed COVID-19 – COVID-NET, 14 States, March 2020 – February 2022. MMWR Morb Mortal Wkly Rep 2022; 71:574581.

  • 3. Nercho PhAnd the Flynn CAnd the Niland RAnd the Subramaniam SSAnd the Hennessy E. Exploring the impact of COVID-19 on mental health outcomes in children and adolescents: a systematic review. Int J Environment Res Public Health 2020; 17:84798479.

  • 4. Mihrali SAnd the Bongani NAnd the Louis Poon S, and others. Child and adolescent mental health amid COVID-19 and previous epidemics: a rapid systematic review. Int J Environment Res Public Health 2021; 18:34323432.

  • 5. Ministry of Health Singapore. Vaccination statistics. February 22And the 2022 (https://www.Moh.Gov.Sg/Covid-19/Vaccination/Statistics).

  • 6. GISAID. Tracing variants: VOC omicron GRA (B.1.1.529 + Ba.*) was first detected in Botswana/Hong Kong/South Africa. February 2022 (https://www.Gisaid.Org/Hcov19-Variants/).

  • 7. Walter E.BAnd the Talaat KrAnd the Sabharwal Si, and others. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. In Angel J Med 2022; 386:3546.

  • 8. Frink RW Jr.And the Klein NPAnd the Kitchen n, and others. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. In Angel J Med 2021; 385:239250.

  • 9. Bar On YMAnd the Goldberg WayAnd the mandel m, and others. Protection of the BNT162b2 booster vaccine against Covid-19 in Israel. In Angel J Med 2021; 385:13931400.

  • 10. Dagan NAnd the cool nAnd the Kepten E., and others. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. In Angel J Med 2021; 384:14121423.

  • 11. gaaraAnd the Undurraga EAAnd the Flores JC, and others. Efficacy of the inactivated SARS-CoV-2 vaccine in children and adolescents: a large-scale observational study. February 15thAnd the 2022 (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4035405). pre-print.

  • 12. Planas dAnd the Saunders InnAnd the miss b, and others. Significant escape of omicron SARS-CoV-2 neutralizing antibody. temper nature 2022; 602:671675.

  • 13. Hoffman mAnd the Kroger nAnd the Schulz S, and others. An omicron variant highly resistant against antibody-mediated neutralization: implications for the control of the COVID-19 pandemic. cell 2022; 185 (3):447.e11456.e11.

  • 14. Ai JAnd the Chang HAnd the Zhang Y, and others. The Omicron variant showed lower neutralization sensitivity than other SARS-CoV-2 variants for post-boost vaccine-induced immune serum. Infects emerging microbes 2022; 11:337343.

  • 15th. Klein NPAnd the Stockwell MSAnd the Demarco m, and others. Efficacy of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccine in Prevention of COVID-19-associated Emergency Department, Urgent Care Meetings and Hospitalization among Non-Compromised Children and Adolescents aged 5-17 – VISION Network, 10 states, April 2021 – January 2022. MMWR Morph Mortal and Clean Rip 2022; 71:352358.

  • 16. VolkswagenAnd the yun skAnd the Lautrec K, and others. Efficacy of a two-dose mRNA vaccine of BNT162b2 (Pfizer BioNTech) in preventing SARS-CoV-2 infection among children aged 5-11 years and adolescents aged 12-15 years – Protection group, July 2021 – February 2022. MMWR Morb Mortal Wkly Rep 2022; 71:422428.

  • 17. Ferdinands JimAnd the Raw SAnd the Dixon B, and others. Efficacy review of two- and three-dose mRNA vaccines against the emergency department associated with COVID-19 and urgent care and hospitalization encounters among adults during delta and omicron variable predominance periods – VISION Network, 10 states, August 2021 – January 2022. MMWR Morp Mortal and Clere Rip 2022; 71:255263.

  • 18. Thomson MGAnd the Natarajan KAnd the Irving SA, and others. Efficacy of a third dose of mRNA vaccines against the emergency department associated with COVID-19 and urgent care encounters and hospitalizations among adults during delta and omicron variable predominance periods – VISION Network, 10 states, August 2021 – January 2022. MMWR Morb Mortal Wkly Rep 2022; 71:139145.

  • 19. price in the morningAnd the Olson SMAnd the Newhams mmAnd the and others. BNT162b2 protection against an omicron variant in children and adolescents. In Angel J Med 2022; 386:18991909.

  • 20. Health Sciences Authority of Singapore. HSA Covid-19 Vaccine Safety Update #11 (December 30, 2020-February 28, 2022). 2022 (https://www.Hsa.Gov.Sg/Docs/Default-Source/Hprg-Vcb/Safety-Update-On-Covid19-Vaccines/Hsa-Safety-Update-No-11-On-Covid-19-Vaccines – (February 28, 2022).pdf.

  • 21. Feldstein LRAnd the MW TinfordAnd the Friedman kg, and others. Characteristics and outcomes of US children and adolescents with pediatric multisystem inflammatory syndrome (MIS-C) compared to severe acute COVID-19. gamma 2021; 325:10741087.

  • 22. Molteni EAnd the Soudrey CHAnd the Canas LS, and others. Duration of illness and profile of symptoms in UK school-age children with symptoms of SARS-CoV-2. The Lancet Baby Adolescent Health 2021; 5:708718.

  • 23. Dattner IAnd the Goldberg WayAnd the Cateril J, and others. The role of children in the spread of COVID-19: Using family data from Bnei Brak, Israel, to estimate the relative susceptibility to infection in children. Plus Compote Bio 2021; 17 (2):e1008559e1008559.

  • 24. Hudson AAnd the Montebury WJ. Vaccine frequency predictions: implications for COVID-19 public health messaging. Int J Environment Res Public Health 2021; 18:80548054.

  • 25. Payne RAnd the Longgate SAnd the Austin Jag, and others. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. cell 2021; 184 (23):5699 AH 115714 / H 11.

  • 26. choi cAnd the confusionAnd the Yoon Koo. Risk factors for severe COVID-19 in children: a systematic review and meta-analysis. J Korean Med Science 2022; 37 (5):e 35e 35.

  • 27. JL WardAnd the Harwood RAnd the Smith C, and others. Risk factors for pediatric intensive care unit admission and death among children and young adults hospitalized with COVID-19 and PIMS-TS in England during the first epidemic year. nat med 2022; 28:193200.

  • 28. Wong JGMAnd the Abbas SAnd the Chuah SL, and others. A comparative analysis of pediatric COVID-19 infection in Southeast Asia, South Asia, Japan and China. I am J Trobe Med Haig 2021; 105:413420.

  • 29. griff kAnd the Tan CakeAnd the Chan FHF, and others. Assessing the rates and determinants of COVID-19 vaccine frequency for adults and children in a Singapore population: Strengthening our community’s resilience to emerging infection threats (SOCRATEs). Vaccines (Basel) 2021; 9:14151415.

  • 30. zimmermann bAnd the Curtis N. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in the severity of SARS-CoV-2 infection. arc dis child 2020; 106:429439.

  • 31. Abdullah FAnd the Myers JAnd the Basso d, and others. Decreased disease severity during the first global spread of the omicron COVID-19 virus in a large hospital in Tshwane, South Africa. Int J Infect Dis 2022; 116:3842.

  • 32. SSA creamAnd the QA . cream. The Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 2021; 398:21262128.

  • 33. Marks KGAnd the Whitaker mAnd the Agathis NT, and others. Hospitalization of infants and children 0-4 years old with laboratory-confirmed COVID-19 virus – COVID-NET, 14 states, March 2020 – February 2022. MMWR Morb Mortal Wkly Rep 2022; 71:429436.

  • Leave a Reply

    %d bloggers like this: